<PAGE>
- -------------------------------------------------------------------------------
SEC 1746 (2-98) POTENTIAL PERSONS WHO ARE TO RESPOND TO THE COLLECTION OF
INFORMATION CONTAINED IN THIS FORM ARE NOT REQUIRED TO RESPOND
UNLESS THE FORM DISPLAYS A CURRENTLY VALID OMB CONTROL NUMBER.
- -------------------------------------------------------------------------------
--------------------------
OMB APPROVAL
--------------------------
UNITED STATES OMB Number: 3235-0145
SECURITIES AND EXCHANGE COMMISSION Expires: October 31, 2002
WASHINGTON, D.C. 20549 Estimated average burden
hours per response... 14.9
--------------------------
SCHEDULE 13D
UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 1 )*
---------
ASTREX, INC.
--------------------------------------------------------
(Name of Issuer)
ASTREX, INC. COMMON STOCK
--------------------------------------------------------
(Title of Class of Securities)
04635-20-8
--------------------------------------------------------
(CUSIP Number)
1750 Euclid Avenue
Cleveland, Ohio 44115
MADAV IX FOUNDATION, ATTN: Barry Reis (216) 566-9200
--------------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
5/5/00
--------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition that is the subject of this Schedule 13D, and is
filing this schedule because of Sections 240.13d-1(e), 240.13d-1(f) or
240.13d-1(g), check the following box. / /
NOTE: Schedules filed in paper format shall include a signed original and
five copies of the schedule, including all exhibits. See Section 240.13d-7 for
other parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter disclosures provided in a prior cover page.
<PAGE>
The information required on the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section
of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).
CUSIP No. 046357208
---------
- -------------------------------------------------------------------------------
(1) Names of Reporting Persons. I.R.S. Identification Nos. of above persons
(entities only).
MADAV IX
--------------------------------------------------------------------------
- -------------------------------------------------------------------------------
(2) Check the Appropriate Box if a Member (a) / /
of a Group (See Instructions) (b) /X/
- -------------------------------------------------------------------------------
(3) SEC Use Only
- -------------------------------------------------------------------------------
(4) Source of Funds (See Instructions) 00
---------------------------------------
- -------------------------------------------------------------------------------
(5) Check if Disclosure of Legal Proceedings Is Required Pursuant to
Items 2(d) or 2(e)
- -------------------------------------------------------------------------------
(6) Citizenship or Place of Organization USA
-------------------------------------
- -------------------------------------------------------------------------------
Number of Shares (7) Sole Voting
Beneficially Owned Power 281025
by Each Reporting --------------------------------------------------
Person With (8) Shared Voting
Power
--------------------------------------------------
(9) Sole Dispositive
Power 281025
--------------------------------------------------
(10) Shared Dispositive
Power
- -------------------------------------------------------------------------------
(11) Aggregate Amount Beneficially Owned by Each Reporting Person 281025
-------------
- -------------------------------------------------------------------------------
(12) Check if the Aggregate Amount in Row (11) Excludes Certain Shares
(See Instructions)
- -------------------------------------------------------------------------------
(13) Percent of Class Represented by Amount in Row (11) 4.9
-----------------------
- -------------------------------------------------------------------------------
(14) Type of Reporting Person (See Instructions) CO
------------------------------
- -------------------------------------------------------------------------------
<PAGE>
the persons named in Item 2 and between such persons and any person with
respect to any securities of the issuer, including but not limited to
transfer or voting of any of the securities, finder's fees, joint ventures,
loan or option arrangements, puts or calls, guarantees of profits, division
of profits or loss, or the giving or withholding of proxies, naming the
persons with whom such contracts, arrangements, understandings or
relationships have been entered into. Include such information for any of the
securities that are pledged or otherwise subject to a contingency the
occurrence of which would give another person voting power or investment
power over such securities except that disclosure of standard default and
similar provisions contained in loan agreements need not be included.
ITEM 7. MATERIAL TO BE FILED AS EXHIBITS
The following shall be filed as exhibits: copies of written agreements
relating to the filing of joint acquisition statements as required by
Section 240.13d-1(k) and copies of all written agreements, contracts,
arrangements, understandings, plans or proposals relating to: (1) the
borrowing of funds to finance the acquisition as disclosed in Item 3; (2) the
acquisition of issuer control, liquidation, sale of assets, merger, or change
in business or corporate structure or any other matter as disclosed in Item
4; and (3) the transfer or voting of the securities, finder's fees, joint
ventures, options, puts, calls, guarantees of loans, guarantees against loss
or of profit, or the giving or withholding of any proxy as disclosed in Item
6.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete
and correct.
5-12-00
- ----------------------------------------
Date
/s/ Barry Reis
- ----------------------------------------
Signature
Barry Reis, Treasurer
- ----------------------------------------
Name/Title
The original statement shall be signed by each person on whose behalf the
statement is filed or his authorized representative. If the statement is
signed on behalf of a person by his authorized representative (other than an
executive officer or general partner of the filing person), evidence of the
representative's authority to sign on behalf of such person shall be filed
with the statement; provided, however, that a power of attorney for this
purpose which is already on file with the Commission may be incorporated by
reference. The name and any title of each person who signs the statement
shall be typed or printed beneath his signature.
ATTENTION: INTENTIONAL MISSTATEMENTS OR OMISSIONS OF FACT
CONSTITUTE FEDERAL CRIMINAL VIOLATIONS (SEE 18 U.S.C. 1001)
<PAGE>
Schedule 13-D
Amendment 1
Cusip # 046357208
ITEM 1. SECURITY AND ISSUER
Astrex, Inc.
205 Express Street
Plainview, NY 11803
(516)433-1700
Michael McGuire, President and CEO
ITEM 4. PURPOSE OF TRANSACTION
Shares were sold for diversification purposes. Madav IX may acquire or
dispose of additional shares based on market conditions.
ITEM 5 INTEREST IN SECURITIES OF THE ISSUER
(a) To the best of the Reporting PERSON's knowledge, there are 5,629,277
shares of the issuer's common stock outstanding. Prior to the
consummation of sale of shares, the Reporting Person owned 375,000
shares or about 6.66 % of the outstanding common stock of, the issuer.
To the best of the Reporting Person's knowledge, there are 5,629,277
shares of the issuer's common stock outstanding. Other than Howard
Amster, none of the Reporting Person's trustees or executive officers
beneficially own any of the issuers's securities.
(b) The Reporting Person has the sole power to vote and dispose of 281,025
shares of common stock identified as beneficially owned by it in Item
5(a).
(c) On 5/8/00 Madav IX ceased to be a 5 % shareholder. During the period
3/14/00 through 5/8/00, Madav IX has sold 93,975 shares of Astrex.
<PAGE>
<TABLE>
<CAPTION>
Quantity
Date Sold Price Proceeds
---- ---- ----- --------
<S> <C> <C> <C>
05/08/2000 15,500 $0.75 $11,462.62
05/05/2000 2,500 $0.78 $1,953.06
05/05/2000 2,500 $0.79 $1,967.93
05/05/2000 5,000 $0.75 $3,699.87
05/05/2000 5,000 $0.81 $4,012.36
05/05/2000 5,000 $0.75 $3,692.87
05/05/2000 15,000 $0.75 $11,249.62
05/01/2000 5,000 $0.75 $3,692.87
04/28/2000 2,230 $0.76 $1,672.44
04/28/2000 3,245 $0.88 $2,839.28
04/28/2000 5,000 $0.75 $3,749.87
04/28/2000 5,000 $0.81 $4,055.36
03/21/2000 3,000 $1.03 $3,086.64
03/20/2000 5,850 $1.00 $5,850.00
03/17/2000 3,150 $0.87 $2,756.00
03/14/2000 11,000 $0.97 $10,688.00
------ ----------
93,975 $76,428.79
</TABLE>
